alfuzosin has been researched along with Bladder Neck Obstruction in 21 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to assess the effect of the selective alpha(1)-blocker alfuzosin on urodynamic parameters and quality of life in female patients with primary bladder neck obstruction (PBNO)." | 9.14 | Effect of alfuzosin on female primary bladder neck obstruction. ( Athanasopoulos, A; Giannitsas, K; Gyftopoulos, K; Perimenis, P, 2009) |
| "The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH)." | 9.08 | Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. ( Casadei, G; Colombo, R; Di Silverio, F; Giberti, C; Martorana, G; Pacifico, P; Rigatti, P; von Heland, M, 1997) |
| "A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha(1)-blocker, on PVR volume and any other associated outcome." | 8.81 | Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. ( Geffriaud-Ricouard, C; Hargreave, TB; McNeill, SA; Roehrborn, CG; Santoni, J, 2001) |
| "The efficacy of alfuzosin in improving lower urinary tract symptoms and relieving bladder outlet obstruction has been demonstrated in numerous short- and long-term placebo-controlled studies and large-scale open studies, involving over 16,000 patients with symptomatic benign prostatic hyperplasia (BPH)." | 8.80 | Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. ( Kirby, RS, 1998) |
| "To determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective alpha1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED)." | 7.74 | Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. ( Agrawal, KC; Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Koka, PS; Sikka, SC, 2008) |
| "A patient who presented with priapism after ingestion of alfuzosin is described." | 7.73 | Stuttering priapism after ingestion of alfuzosin. ( Ananthakrishnan, K; Fordham, MV; Manikandan, R; Qazi, HA, 2006) |
| "To evaluate the efficacy of alfuzosin treatment on voiding and storage in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) with respect to bladder outlet obstruction and contractility." | 5.15 | The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility. ( Cho, JS; Choo, MS; Han, JY; Kim, JC; Lee, KS; Lee, YS; Song, K, 2011) |
| "Our objective was to assess the effect of the selective alpha(1)-blocker alfuzosin on urodynamic parameters and quality of life in female patients with primary bladder neck obstruction (PBNO)." | 5.14 | Effect of alfuzosin on female primary bladder neck obstruction. ( Athanasopoulos, A; Giannitsas, K; Gyftopoulos, K; Perimenis, P, 2009) |
| "To assess the symptomatic outcome following transurethral prostatectomy (TURP), alpha-blockade and placebo treatment in uncomplicated benign prostatic hyperplasia (BPH), 260 patients were evaluated with the recently formulated Danish Prostatic Symptom Score (DAN-PSS-1) system: 205 were randomized to either the selective alpha-blocker alfuzosin or placebo and 55 underwent TURP." | 5.08 | Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group. ( Flyger, H; Hansen, BJ; Mensink, HJ; Meyhoff, HH; Mortensen, S, 1996) |
| "The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH)." | 5.08 | Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. ( Casadei, G; Colombo, R; Di Silverio, F; Giberti, C; Martorana, G; Pacifico, P; Rigatti, P; von Heland, M, 1997) |
| "A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha(1)-blocker, on PVR volume and any other associated outcome." | 4.81 | Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. ( Geffriaud-Ricouard, C; Hargreave, TB; McNeill, SA; Roehrborn, CG; Santoni, J, 2001) |
| "The efficacy of alfuzosin in improving lower urinary tract symptoms and relieving bladder outlet obstruction has been demonstrated in numerous short- and long-term placebo-controlled studies and large-scale open studies, involving over 16,000 patients with symptomatic benign prostatic hyperplasia (BPH)." | 4.80 | Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia. ( Kirby, RS, 1998) |
| "To determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective alpha1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED)." | 3.74 | Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. ( Agrawal, KC; Chandra, S; Gur, S; Hellstrom, WJ; Kadowitz, PJ; Koka, PS; Sikka, SC, 2008) |
| "A patient who presented with priapism after ingestion of alfuzosin is described." | 3.73 | Stuttering priapism after ingestion of alfuzosin. ( Ananthakrishnan, K; Fordham, MV; Manikandan, R; Qazi, HA, 2006) |
| "The aim of our study was to evaluate the symptomatic and urodynamic changes after 1-5 years of treatment with alfuzosin in patients with benign prostatic hyperplasia." | 3.72 | Clinical and pressure-flow changes after long-term treatment with alfuzosin SR. ( De Nunzio, C; Franco, G; Iori, F; Laurenti, C; Leonardo, C; Minardi, V, 2003) |
| "With tamsulosin treatment, both mesopic and scotopic PD decreased, respectively, from 3." | 2.73 | The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study. ( Adibelli, FM; Akova, YA; Altan-Yaycioglu, R; Gul, U; Pelit, A; Yaycioglu, O, 2007) |
| "alpha(1)-Blockers were effective and safe for treating young and middle-aged men with symptomatic bladder neck obstruction." | 2.72 | Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers. ( Artibani, W; Calpista, A; Cisternino, A; De Marco, V; Iafrate, M; Prayer Galetti, T; Zeccolini, G, 2006) |
| "Alfuzosina has a specific antagonist effect on the alfa-1-adrenergic post-junctional receptor posed at urethral laeve musculature, prostatic capsule and vesical trgonum." | 2.67 | [Assessment of the effects of alfuzosin on miction with dynamic echography]. ( Gentili, G; Mautone, A; Milani, M; Tucci, G, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Athanasopoulos, A | 1 |
| Gyftopoulos, K | 1 |
| Giannitsas, K | 1 |
| Perimenis, P | 1 |
| Gur, S | 1 |
| Sikka, SC | 1 |
| Chandra, S | 1 |
| Koka, PS | 1 |
| Agrawal, KC | 1 |
| Kadowitz, PJ | 1 |
| Hellstrom, WJ | 1 |
| Koh, JS | 1 |
| Kim, SJ | 1 |
| Kim, HS | 1 |
| Kim, JC | 2 |
| Lee, YS | 2 |
| Lee, HN | 1 |
| Han, JY | 2 |
| Choo, MS | 2 |
| Lee, KS | 2 |
| Song, K | 1 |
| Cho, JS | 1 |
| De Nunzio, C | 1 |
| Franco, G | 1 |
| Iori, F | 1 |
| Leonardo, C | 1 |
| Minardi, V | 1 |
| Laurenti, C | 1 |
| van Moorselaar, RJ | 1 |
| Hartung, R | 1 |
| Emberton, M | 1 |
| Harving, N | 1 |
| Matzkin, H | 1 |
| Elhilali, M | 1 |
| Alcaraz, A | 1 |
| Vallancien, G | 1 |
| Seftel, A | 1 |
| Cisternino, A | 1 |
| Zeccolini, G | 1 |
| Calpista, A | 1 |
| De Marco, V | 1 |
| Prayer Galetti, T | 1 |
| Iafrate, M | 1 |
| Artibani, W | 1 |
| Qazi, HA | 1 |
| Ananthakrishnan, K | 1 |
| Manikandan, R | 1 |
| Fordham, MV | 1 |
| Altan-Yaycioglu, R | 1 |
| Yaycioglu, O | 1 |
| Gul, U | 1 |
| Pelit, A | 1 |
| Adibelli, FM | 1 |
| Akova, YA | 1 |
| Mariappan, P | 1 |
| Brown, DJ | 1 |
| McNeill, AS | 1 |
| Milani, M | 1 |
| Mautone, A | 1 |
| Tucci, G | 1 |
| Gentili, G | 1 |
| Hansen, BJ | 1 |
| Flyger, H | 1 |
| Mortensen, S | 1 |
| Mensink, HJ | 1 |
| Meyhoff, HH | 1 |
| Martorana, G | 1 |
| Giberti, C | 1 |
| Di Silverio, F | 1 |
| von Heland, M | 1 |
| Rigatti, P | 1 |
| Colombo, R | 1 |
| Casadei, G | 1 |
| Pacifico, P | 1 |
| Kirby, RS | 1 |
| Rossi, C | 1 |
| Kortmann, BB | 1 |
| Sonke, GS | 1 |
| Floratos, DL | 1 |
| Kiemeney, LA | 1 |
| Wijkstra, H | 1 |
| de la ROSETTE, JJ | 1 |
| McNeill, SA | 1 |
| Hargreave, TB | 1 |
| Geffriaud-Ricouard, C | 1 |
| Santoni, J | 1 |
| Roehrborn, CG | 1 |
| Chess-Williams, R | 1 |
| Ramsay, JW | 1 |
| Scott, GI | 1 |
| Whitfield, HN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility[NCT00836823] | Phase 4 | 130 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for alfuzosin and Bladder Neck Obstruction
| Article | Year |
|---|---|
Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Delayed-Action Preparations; Humans; Hypotension, Orth | 1998 |
Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
Topics: Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Humans; Male; Middle Aged | 2001 |
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfo | 2002 |
11 trials available for alfuzosin and Bladder Neck Obstruction
| Article | Year |
|---|---|
Effect of alfuzosin on female primary bladder neck obstruction.
Topics: Adrenergic alpha-Antagonists; Female; Humans; Middle Aged; Patient Satisfaction; Prospective Studies | 2009 |
Comparison of alpha-blocker, extracorporeal magnetic stimulation alone and in combination in the management of female bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Adult; Combined Modality Therapy; Female; Humans; Magnetic Field Thera | 2011 |
Most bothersome symptom and symptom specific goal achievement in patients with benign prostatic obstruction: a prospective open label study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Goals; Humans; Male; Middle Aged; Prospective Studies; Pros | 2011 |
The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Muscle | 2011 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Ejaculation; Humans; Male; Pain; Penile Erection; Quality of Lif | 2005 |
Obstructive primary bladder neck disease: evaluation of the efficacy and safety of alpha1-blockers.
Topics: Adrenergic alpha-Antagonists; Adult; Humans; Male; Middle Aged; Quinazolines; Sulfonamides; Tamsulos | 2006 |
The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Humans; Intraoperative | 2007 |
[Assessment of the effects of alfuzosin on miction with dynamic echography].
Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Humans; Male; Prostatic Hyperplasia; Quinazolines | 1994 |
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Follow-Up Studies; Humans; Male; Middle Aged; | 1996 |
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Follow-Up Studies; Human | 1997 |
A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Middle Aged; Pro | 1985 |
7 other studies available for alfuzosin and Bladder Neck Obstruction
| Article | Year |
|---|---|
Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction.
Topics: Adrenergic alpha-Antagonists; Animals; Blotting, Western; Erectile Dysfunction; Immunohistochemistry | 2008 |
Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazo | 2003 |
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2005 |
Stuttering priapism after ingestion of alfuzosin.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Priapism; Quinazolines; Urinary Bladder Nec | 2006 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; | 2007 |
[Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Humans; Male | 1995 |
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Middle Aged; Prazosin; Quinazolines; Severity of Illness | 2001 |